Osteopontin predicts clinical outcome in patients after treatment of severe aortic stenosis with transcatheter aortic valve implantation (TAVI).

摘要: Objective Osteopontin (OPN) is an extracellular matrix protein that plays integral role in myocardial remodelling and has previously been shown to be a valuable biomarker cardiovascular disease. Because of the concentric hypertrophy associated with severe, symptomatic aortic stenosis (AS), we hypothesised OPN expression may have prognostic value patients undergoing transcatheter valve implantation (TAVI). Methods We prospectively included 217 TAVI between February 2011 December 2013 median follow-up 349 days. Twenty healthy individuals from same age range free structural heart disease served as controls. The primary endpoint for analysis was survival time. Results Median preprocedural levels (675 ng/mL; IQR 488.5–990.5 ng/mL) were significantly higher severe compared controls (386 ng/mL; 324.5–458, p Conclusions at baseline are adverse outcomes AS TAVI.